Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - flecainide acetate - oral tablet - 50mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - flecainide acetate - oral tablet - 100mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - flecainide acetate - oral tablet - 100mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 10 mg/ml - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; water for injections - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir